Can tenecteplase (TNKase) be administered for an acute ischemic stroke in a patient with an Achilles tendon tear who is on dual antiplatelet therapy?

Can TNKase Be Given for Stroke with Achilles Tendon Tear and Dual Antiplatelet Therapy?

Yes, TNKase (tenecteplase) can be administered for acute ischemic stroke in this patient, as dual antiplatelet therapy is not a contraindication and an Achilles tendon tear does not represent a bleeding risk that would preclude thrombolytic therapy.

Dual Antiplatelet Therapy is NOT a Contraindication

The 2018 AHA/ASA Guidelines explicitly state that IV alteplase (and by extension tenecteplase) is recommended for patients taking antiplatelet drug combination therapy (e.g., aspirin and clopidogrel) before stroke, based on evidence that the benefit outweighs a probable increased risk of symptomatic intracranial hemorrhage 1. This is a Class I recommendation with Level of Evidence B-NR, meaning there is strong evidence supporting this practice.

• The guidelines acknowledge a probable increased risk of symptomatic ICH with dual antiplatelet therapy, but the benefit of thrombolysis still outweighs this risk
• Recent real-world data from 2025 confirms no significant difference in symptomatic ICH rates between patients on antiplatelets versus those not on these medications when receiving thrombolysis 2
• Patients on dual antiplatelets may have slightly worse functional outcomes (higher mRS), but this reflects underlying comorbidities rather than procedural complications 2

Achilles Tendon Tear is NOT a Contraindication

The FDA label for TNKase and AHA/ASA guidelines do not list peripheral musculoskeletal injuries as contraindications 3. The contraindications focus on:

• Active internal bleeding
• Recent severe head trauma (within 3 months)
• Intracranial/intraspinal surgery within 3 months
• GI malignancy or GI bleed within 21 days
• Coagulopathy

An Achilles tendon tear is a closed musculoskeletal injury that does not pose significant bleeding risk comparable to the contraindicated conditions. The primary bleeding concerns with thrombolytics involve:

• Intracranial hemorrhage
• Internal bleeding from compressible and non-compressible sites
• Recent surgery or trauma to critical areas

Practical Considerations for the Achilles Tear:

• Avoid unnecessary manipulation of the injured extremity during and after thrombolytic administration
• If the patient requires immobilization or casting, this can be performed after thrombolysis
• The tear itself is not a source of life-threatening bleeding
• Standard precautions apply: avoid arterial punctures in that limb if possible

TNKase vs Alteplase: Current Evidence

While the guidelines list tenecteplase as a Class IIb recommendation (may be considered as alternative to alteplase in patients with minor neurological impairment and no major intracranial occlusion) 1, the most recent 2024-2025 evidence strongly supports TNKase as equivalent or superior to alteplase:

• 2024 meta-analysis of phase III trials: TNK 0.25 mg/kg was non-inferior to alteplase for excellent functional outcome (mRS 0-1) with similar safety profile 4
• 2024 updated meta-analysis: TNK was superior to alteplase for excellent functional outcome (RR 1.05, p=0.012) and reduced disability, with no difference in symptomatic ICH or mortality 5
• 2024 ORIGINAL trial (largest single trial, n=1489): TNK was non-inferior to alteplase with similar safety 6
• 2025 real-world data from Get With The Guidelines registry (79,550 patients): Similar effectiveness and safety between TNK and alteplase 7

Clinical Algorithm for This Patient

Proceed with TNKase if:

1. ✓ Patient presents within 4.5 hours of symptom onset (or meets extended window criteria with advanced imaging)
2. ✓ No absolute contraindications present (see list above)
3. ✓ Blood pressure can be controlled to <185/110 mmHg
4. ✓ Coagulation parameters normal (if on dual antiplatelets alone, no need to wait for labs unless history suggests coagulopathy)

Dosing:

• TNKase 0.25 mg/kg (or 0.4 mg/kg per some protocols) as single IV bolus over 5 seconds 3
• Simpler administration than alteplase (single bolus vs 60-minute infusion)

Post-Administration Management:

• Continue standard stroke monitoring protocols
• Avoid arterial punctures in the affected limb with Achilles tear
• Monitor for bleeding complications per standard protocols
• The dual antiplatelet therapy does not require discontinuation immediately post-thrombolysis

Common Pitfalls to Avoid

1. Do not withhold thrombolysis based on dual antiplatelet therapy—this is explicitly addressed in guidelines as acceptable
2. Do not delay treatment to obtain unnecessary consultations about the Achilles tear
3. Do not confuse peripheral musculoskeletal injuries with contraindicated conditions like recent major surgery or active bleeding
4. Do not wait for platelet counts if patient has no history of thrombocytopenia and is only on antiplatelets (can initiate and discontinue if platelets <100,000) 1

The benefit of restoring cerebral perfusion and preventing permanent disability from stroke far outweighs the theoretical bleeding concerns in this clinical scenario.